Poly-publications on the polypharmacology of kinase/bromodomains dual inhibitors

When you consider how vast the chemical space is and how restricted the topology and chemical environment of a specific pocket in a protein is, it’s quite surprising we can find molecules that the protein was not evolved to bind that can nonetheless bind and inhibit it potently. It is therefore even more surprising when a single molecule can potently hit two completely unrelated (by sequence, by structure and by function) proteins. Thus, when two independent groups publish such dual kinase/bromodomain inhibitors a week a part from each other, the mind reels.



Why did PAINS hit a nerve?

“CDD spotlight” recently interviewed prof. Jonathan Baell the author of the notorious PAINS paper.

PAINS or Pan Assay Interference Compounds, are a class of compounds that commonly show up in high throughput screens (HTS) for small molecule inhibitors (you can read more about them here , here  and here).

When asked why in his opinion this paper made such an impact, Baell gave an interesting answer: basically it really hit a nerve, and the timing was just right. According to Baell, their group lead some of the first academic HTS efforts, and stumbled upon these PAINS molecules again and again. By the time the paper was published, there were probably dozens of academic labs performing screens and it really resonated with them. Another possible reason for the wide acceptance of this work might have been ex-pharma people, turned academics, who knew these molecules from their past but could not talk about them. Baell mentions for instance that for Chris Lipinski “it was a breath of fresh air…”.

From a practical stand-point you can use this server from the Oprea group to filter your molecules and avoid future PAINS.



Written by Nir London in: Interviews | Tags: , , ,

Powered by WordPress | Aeros Theme | WordPress Themes
© 2009 Rosetta Design Group LLC